ALB and breast carcinoma: In addition, cytotoxicity and cell uptake experiments showed that, after encapsulation of Nintedanib into folic acid modified albumin microspheres, the cell uptake ability of the drug was significantly enhanced, while the inhibition rate of breast cancer cell MCF-7 was higher.